ArticleFrontiers in oncology2025

Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and

Julia Forschner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.